10:37 AM EST, 02/06/2025 (MT Newswires) -- Insmed ( INSM ) said Thursday that the US Food and Drug Administration accepted its new drug application for brensocatib to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition.

The US regulator granted priority review to the new drug application and has set a target action date of Aug. 12, according to the company.

The application is based on data from the phase 3 Aspen study that showed brensocatib, at both doses tested, significantly reduced lung flare-ups and lowered lung function decline compared to a placebo over one year, Ismed added.

The company said it plans to file regulatory submissions for brensocatib in the European Union, UK and Japan in 2025.

Price: 81.00, Change: -0.44, Percent Change: -0.55